Amgen IncChange company Symbol lookupSelect an option...AMGN Amgen IncBAC Bank of America CorpCLOV Clover Health Investments CorpHRL Hormel Foods CorpDD Dupont De Nemours IncPSRU Valiant Eagle IncCRM Salesforce.Com IncVLYPP Valley National BancorpFEMKX Fidelity® Emerging Markets FundXPEV Xpeng IncGo
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
AMGN's position in the Biotechnology industry
| Industry Peers | ABBV | GILD | VRTX | REGN | |
|---|---|---|---|---|---|
Summary | |||||
| Company Profile | Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products... | AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are... Go to ABBV summary | Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and... Go to GILD summary | Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing... Go to VRTX summary | Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The... Go to REGN summary |
| 52-Week Change | VS. INDUSTRY | 21.60% | -16.43% | -8.71% | -2.13% |
| Market Cap | VS. INDUSTRY | $191.4B | $78.5B | $54.7B | $49.6B |
| Beta | VS. INDUSTRY | 0.8 | 0.4 | 0.7 | 0.2 |
| Dividend Yield | VS. INDUSTRY | 4.80% | 4.55% | -- | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | 40.01x | 1,096.56x | 20.42x | 15.09x |
| Data as of | |||||
Fundamentals | |||||
| Total Revenue (TTM) | VS. INDUSTRY | $45.8B | $24.7B | $6.2B | $8.5B |
| Profit Margin | VS. INDUSTRY | 10.09% | 0.36% | 43.70% | 41.35% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | -2.82% | -61.76% | -- | 40.78% |
| Revenue Growth (TTM) | VS. INDUSTRY | 37.69% | 9.98% | 49.07% | 23.80% |
| Data as of |
Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.